Does the media favor TWST or DNA?

In the previous week, Twist Bioscience had 13 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 17 mentions for Twist Bioscience and 4 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.29 beat Ginkgo Bioworks' score of 0.57 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, TWST or ILMN?

Illumina has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $431.80M 20.53 -$77.67M -$2.22 N/A Illumina $4.49B 7.24 $850M $5.36 40.22

Does the media refer more to TWST or ILMN?

In the previous week, Illumina had 34 more articles in the media than Twist Bioscience. MarketBeat recorded 51 mentions for Illumina and 17 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.29 beat Illumina's score of 1.15 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 38 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TWST or MTD?

In the previous week, Mettler-Toledo International had 8 more articles in the media than Twist Bioscience. MarketBeat recorded 25 mentions for Mettler-Toledo International and 17 mentions for Twist Bioscience. Mettler-Toledo International's average media sentiment score of 1.54 beat Twist Bioscience's score of 1.29 indicating that Mettler-Toledo International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mettler-Toledo International 24 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, TWST or MEDP?

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $431.80M 20.53 -$77.67M -$2.22 N/A Medpace $2.78B 6.03 $451.12M $17.06 35.21

Is TWST or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -31.66% -28.64% -19.94% Medpace 17.67% 110.15% 24.84%

Does the media prefer TWST or MEDP?

In the previous week, Medpace had 30 more articles in the media than Twist Bioscience. MarketBeat recorded 47 mentions for Medpace and 17 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.29 beat Medpace's score of 1.07 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 34 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, RVTY or TWST?

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 5.04 $241.20M $2.10 61.37 Twist Bioscience $431.80M 20.53 -$77.67M -$2.22 N/A

Does the media prefer RVTY or TWST?

In the previous week, Revvity had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 32 mentions for Revvity and 17 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.29 beat Revvity's score of 0.98 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 17 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Twist Bioscience (TWST) Competitors

$141.38 -11.72 (-7.66%)

As of 08/28/2026 04:00 PM Eastern

Compare

TWST vs. DNA, ILMN, MTD, MEDP, and RVTY

Should you buy Twist Bioscience stock or one of its competitors? Twist Bioscience's main competitors and comparable companies include Ginkgo Bioworks (DNA), Illumina (ILMN), Mettler-Toledo International (MTD), Medpace (MEDP), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Twist Bioscience compare to Ginkgo Bioworks?

Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Twist Bioscience presently has a consensus target price of $98.30, suggesting a potential downside of 30.47%. Ginkgo Bioworks has a consensus target price of $7.00, suggesting a potential upside of 0.29%. Given Ginkgo Bioworks' higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -259.96%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

In the previous week, Twist Bioscience had 13 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 17 mentions for Twist Bioscience and 4 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.29 beat Ginkgo Bioworks' score of 0.57 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Twist Bioscience has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	20.53	-$77.67M	-$2.22	N/A
Ginkgo Bioworks	$170.15M	2.76	-$312.76M	-$5.01	N/A

78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Illumina?

Twist Bioscience (NASDAQ:TWST) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Illumina has a net margin of 18.36% compared to Twist Bioscience's net margin of -31.66%. Illumina's return on equity of 29.84% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Illumina	18.36%	29.84%	12.17%

Twist Bioscience has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Illumina has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

89.4% of Illumina shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Illumina has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	20.53	-$77.67M	-$2.22	N/A
Illumina	$4.49B	7.24	$850M	$5.36	40.22

In the previous week, Illumina had 34 more articles in the media than Twist Bioscience. MarketBeat recorded 51 mentions for Illumina and 17 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.29 beat Illumina's score of 1.15 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	38 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Twist Bioscience presently has a consensus price target of $98.30, suggesting a potential downside of 30.47%. Illumina has a consensus price target of $188.40, suggesting a potential downside of 12.61%. Given Illumina's higher possible upside, analysts plainly believe Illumina is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Summary

Illumina beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Mettler-Toledo International?

Twist Bioscience (NASDAQ:TWST) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

95.1% of Mettler-Toledo International shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mettler-Toledo International has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	20.53	-$77.67M	-$2.22	N/A
Mettler-Toledo International	$4.03B	6.95	$869.19M	$44.43	31.44

In the previous week, Mettler-Toledo International had 8 more articles in the media than Twist Bioscience. MarketBeat recorded 25 mentions for Mettler-Toledo International and 17 mentions for Twist Bioscience. Mettler-Toledo International's average media sentiment score of 1.54 beat Twist Bioscience's score of 1.29 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mettler-Toledo International	24 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Twist Bioscience has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Twist Bioscience currently has a consensus target price of $98.30, suggesting a potential downside of 30.47%. Mettler-Toledo International has a consensus target price of $1,461.27, suggesting a potential upside of 4.60%. Given Mettler-Toledo International's higher probable upside, analysts clearly believe Mettler-Toledo International is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Mettler-Toledo International	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Mettler-Toledo International has a net margin of 21.91% compared to Twist Bioscience's net margin of -31.66%. Twist Bioscience's return on equity of -28.64% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

Summary

Mettler-Toledo International beats Twist Bioscience on 10 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Medpace?

Twist Bioscience (NASDAQ:TWST) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Twist Bioscience currently has a consensus price target of $98.30, suggesting a potential downside of 30.47%. Medpace has a consensus price target of $584.18, suggesting a potential downside of 2.74%. Given Medpace's higher possible upside, analysts clearly believe Medpace is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Twist Bioscience has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Medpace	17.67%	110.15%	24.84%

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	20.53	-$77.67M	-$2.22	N/A
Medpace	$2.78B	6.03	$451.12M	$17.06	35.21

In the previous week, Medpace had 30 more articles in the media than Twist Bioscience. MarketBeat recorded 47 mentions for Medpace and 17 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.29 beat Medpace's score of 1.07 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	34 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.0% of Medpace shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Medpace beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Revvity?

Revvity (NYSE:RVTY) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Revvity currently has a consensus target price of $108.36, suggesting a potential downside of 15.92%. Twist Bioscience has a consensus target price of $98.30, suggesting a potential downside of 30.47%. Given Revvity's higher possible upside, research analysts plainly believe Revvity is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

86.7% of Revvity shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 3.1% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	5.04	$241.20M	$2.10	61.37
Twist Bioscience	$431.80M	20.53	-$77.67M	-$2.22	N/A

Revvity has a net margin of 8.16% compared to Twist Bioscience's net margin of -31.66%. Revvity's return on equity of 8.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Twist Bioscience	-31.66%	-28.64%	-19.94%

In the previous week, Revvity had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 32 mentions for Revvity and 17 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.29 beat Revvity's score of 0.98 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	17 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Summary

Revvity beats Twist Bioscience on 10 of the 16 factors compared between the two stocks.

Get Twist Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TWST vs. The Competition

Export

Metric	Twist Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.87B	$10.11B	$7.20B	$12.90B
Dividend Yield	N/A	1.46%	2.54%	11.28%
P/E Ratio	-63.68	62.76	273.16	25.45
Price / Sales	20.53	111.63	605.01	76.63
Price / Cash	N/A	26.70	76.74	53.00
Price / Book	19.88	37.29	12.98	6.14
Net Income	-$77.67M	$56.67B	$3.48B	$348.86M
7 Day Performance	-2.89%	-1.52%	0.13%	-0.80%
1 Month Performance	54.80%	7.21%	7.08%	4.13%
1 Year Performance	424.21%	24.31%	24.67%	15.17%

Twist Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TWST Twist Bioscience	1.6717 of 5 stars	$141.38 -7.7%	$98.30 -30.5%	+424.2%	$8.87B	$431.80M	N/A	990	Positive News Insider Trade
DNA Ginkgo Bioworks	0.9376 of 5 stars	$7.29 +0.8%	$7.00 -3.9%	-45.1%	$486.87M	$170.15M	N/A	640
ILMN Illumina	2.5288 of 5 stars	$227.69 +1.3%	$188.40 -17.3%	+115.7%	$33.95B	$4.34B	42.48	8,650	Trending News Insider Trade
MTD Mettler-Toledo International	3.9113 of 5 stars	$1,407.20 +0.6%	$1,461.27 +3.8%	+7.2%	$28.02B	$4.03B	31.67	18,100	News Coverage Positive News
MEDP Medpace	3.1758 of 5 stars	$611.57 -1.2%	$584.18 -4.5%	+26.3%	$17.28B	$2.53B	35.85	6,200	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TWST) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Competitors

TWST vs. DNA, ILMN, MTD, MEDP, and RVTY

How does Twist Bioscience compare to Ginkgo Bioworks?

Summary

How does Twist Bioscience compare to Illumina?

Summary

How does Twist Bioscience compare to Mettler-Toledo International?

Summary

How does Twist Bioscience compare to Medpace?

Summary

How does Twist Bioscience compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Competitors

TWST vs. DNA, ILMN, MTD, MEDP, and RVTY

How does Twist Bioscience compare to Ginkgo Bioworks?

Do analysts rate TWST or DNA?

Is TWST or DNA more profitable?

Does the media favor TWST or DNA?

Which has more volatility and risk, TWST or DNA?

Which has preferable earnings and valuation, TWST or DNA?

Do insiders & institutionals have more ownership in TWST or DNA?

Summary

How does Twist Bioscience compare to Illumina?

Is TWST or ILMN more profitable?

Which has more volatility & risk, TWST or ILMN?

Do institutionals and insiders have more ownership in TWST or ILMN?

Which has stronger valuation and earnings, TWST or ILMN?

Does the media refer more to TWST or ILMN?

Do analysts rate TWST or ILMN?

Summary

How does Twist Bioscience compare to Mettler-Toledo International?

Do institutionals & insiders have more ownership in TWST or MTD?

Which has better earnings & valuation, TWST or MTD?

Does the media refer more to TWST or MTD?

Which has more risk and volatility, TWST or MTD?

Do analysts rate TWST or MTD?

Is TWST or MTD more profitable?

Summary

How does Twist Bioscience compare to Medpace?

Do analysts rate TWST or MEDP?

Which has more volatility and risk, TWST or MEDP?

Is TWST or MEDP more profitable?

Which has stronger earnings and valuation, TWST or MEDP?

Does the media prefer TWST or MEDP?

Do insiders & institutionals hold more shares of TWST or MEDP?

Summary

How does Twist Bioscience compare to Revvity?

Do analysts recommend RVTY or TWST?

Do institutionals and insiders hold more shares of RVTY or TWST?

Which has better valuation & earnings, RVTY or TWST?

Is RVTY or TWST more profitable?

Does the media prefer RVTY or TWST?

Which has more risk & volatility, RVTY or TWST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools